Biologics and Biosimilars-Global Market Status & Trend Report 2015-2026 Top 20 Countries Data
Report Summary
Biologics and Biosimilars-Global Market Status & Trend Report 2015-2026 Top 20 Countries Data offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Biologics and Biosimilars 2015-2019, and development forecast 2020-2026
Main manufacturers/suppliers of Biologics and Biosimilars worldwide and market share by regions, with company and product introduction, position in the Biologics and Biosimilars market
Market status and development trend of Biologics and Biosimilars by types and applications
Cost and profit status of Biologics and Biosimilars, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Biologics and Biosimilars market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.
The report segments the global Biologics and Biosimilars market as:
Global Biologics and Biosimilars Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Biologics and Biosimilars Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Global Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Global Biologics and Biosimilars Market: Manufacturers Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Eli Lilly
Sanofi-Aventis
Amgen
Novo Nordisk
AbbVie
Merck
Pfizer
Johnson & Johnson
Novartis
Gelgen
Ganlee
3sbio
Innovent
Biotech
Changchun High Tech
Dong Bao
CP Guojian
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biologics and Biosimilars-Global Market Status & Trend Report 2015-2026 Top 20 Countries Data offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Biologics and Biosimilars 2015-2019, and development forecast 2020-2026
Main manufacturers/suppliers of Biologics and Biosimilars worldwide and market share by regions, with company and product introduction, position in the Biologics and Biosimilars market
Market status and development trend of Biologics and Biosimilars by types and applications
Cost and profit status of Biologics and Biosimilars, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Biologics and Biosimilars market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.
The report segments the global Biologics and Biosimilars market as:
Global Biologics and Biosimilars Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Biologics and Biosimilars Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Global Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Global Biologics and Biosimilars Market: Manufacturers Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Eli Lilly
Sanofi-Aventis
Amgen
Novo Nordisk
AbbVie
Merck
Pfizer
Johnson & Johnson
Novartis
Gelgen
Ganlee
3sbio
Innovent
Biotech
Changchun High Tech
Dong Bao
CP Guojian
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOLOGICS AND BIOSIMILARS
1.1 Definition of Biologics and Biosimilars in This Report
1.2 Commercial Types of Biologics and Biosimilars
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Erythropoietin
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Downstream Application of Biologics and Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Others
1.4 Development History of Biologics and Biosimilars
1.5 Market Status and Trend of Biologics and Biosimilars 2015-2026
1.5.1 Global Biologics and Biosimilars Market Status and Trend 2015-2026
1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2015-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Biologics and Biosimilars 2015-2019
2.2 Sales Market of Biologics and Biosimilars by Regions
2.2.1 Sales Volume of Biologics and Biosimilars by Regions
2.2.2 Sales Value of Biologics and Biosimilars by Regions
2.3 Production Market of Biologics and Biosimilars by Regions
2.4 Global Market Forecast of Biologics and Biosimilars 2020-2026
2.4.1 Global Market Forecast of Biologics and Biosimilars 2020-2026
2.4.2 Market Forecast of Biologics and Biosimilars by Regions 2020-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Biologics and Biosimilars by Types
3.2 Sales Value of Biologics and Biosimilars by Types
3.3 Market Forecast of Biologics and Biosimilars by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Biologics and Biosimilars by Downstream Industry
4.2 Global Market Forecast of Biologics and Biosimilars by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Biologics and Biosimilars Market Status by Countries
5.1.1 North America Biologics and Biosimilars Sales by Countries (2015-2019)
5.1.2 North America Biologics and Biosimilars Revenue by Countries (2015-2019)
5.1.3 United States Biologics and Biosimilars Market Status (2015-2019)
5.1.4 Canada Biologics and Biosimilars Market Status (2015-2019)
5.1.5 Mexico Biologics and Biosimilars Market Status (2015-2019)
5.2 North America Biologics and Biosimilars Market Status by Manufacturers
5.3 North America Biologics and Biosimilars Market Status by Type (2015-2019)
5.3.1 North America Biologics and Biosimilars Sales by Type (2015-2019)
5.3.2 North America Biologics and Biosimilars Revenue by Type (2015-2019)
5.4 North America Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Biologics and Biosimilars Market Status by Countries
6.1.1 Europe Biologics and Biosimilars Sales by Countries (2015-2019)
6.1.2 Europe Biologics and Biosimilars Revenue by Countries (2015-2019)
6.1.3 Germany Biologics and Biosimilars Market Status (2015-2019)
6.1.4 UK Biologics and Biosimilars Market Status (2015-2019)
6.1.5 France Biologics and Biosimilars Market Status (2015-2019)
6.1.6 Italy Biologics and Biosimilars Market Status (2015-2019)
6.1.7 Russia Biologics and Biosimilars Market Status (2015-2019)
6.1.8 Spain Biologics and Biosimilars Market Status (2015-2019)
6.1.9 Benelux Biologics and Biosimilars Market Status (2015-2019)
6.2 Europe Biologics and Biosimilars Market Status by Manufacturers
6.3 Europe Biologics and Biosimilars Market Status by Type (2015-2019)
6.3.1 Europe Biologics and Biosimilars Sales by Type (2015-2019)
6.3.2 Europe Biologics and Biosimilars Revenue by Type (2015-2019)
6.4 Europe Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Biologics and Biosimilars Market Status by Countries
7.1.1 Asia Pacific Biologics and Biosimilars Sales by Countries (2015-2019)
7.1.2 Asia Pacific Biologics and Biosimilars Revenue by Countries (2015-2019)
7.1.3 China Biologics and Biosimilars Market Status (2015-2019)
7.1.4 Japan Biologics and Biosimilars Market Status (2015-2019)
7.1.5 India Biologics and Biosimilars Market Status (2015-2019)
7.1.6 Southeast Asia Biologics and Biosimilars Market Status (2015-2019)
7.1.7 Australia Biologics and Biosimilars Market Status (2015-2019)
7.2 Asia Pacific Biologics and Biosimilars Market Status by Manufacturers
7.3 Asia Pacific Biologics and Biosimilars Market Status by Type (2015-2019)
7.3.1 Asia Pacific Biologics and Biosimilars Sales by Type (2015-2019)
7.3.2 Asia Pacific Biologics and Biosimilars Revenue by Type (2015-2019)
7.4 Asia Pacific Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Biologics and Biosimilars Market Status by Countries
8.1.1 Latin America Biologics and Biosimilars Sales by Countries (2015-2019)
8.1.2 Latin America Biologics and Biosimilars Revenue by Countries (2015-2019)
8.1.3 Brazil Biologics and Biosimilars Market Status (2015-2019)
8.1.4 Argentina Biologics and Biosimilars Market Status (2015-2019)
8.1.5 Colombia Biologics and Biosimilars Market Status (2015-2019)
8.2 Latin America Biologics and Biosimilars Market Status by Manufacturers
8.3 Latin America Biologics and Biosimilars Market Status by Type (2015-2019)
8.3.1 Latin America Biologics and Biosimilars Sales by Type (2015-2019)
8.3.2 Latin America Biologics and Biosimilars Revenue by Type (2015-2019)
8.4 Latin America Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Biologics and Biosimilars Market Status by Countries
9.1.1 Middle East and Africa Biologics and Biosimilars Sales by Countries (2015-2019)
9.1.2 Middle East and Africa Biologics and Biosimilars Revenue by Countries (2015-2019)
9.1.3 Middle East Biologics and Biosimilars Market Status (2015-2019)
9.1.4 Africa Biologics and Biosimilars Market Status (2015-2019)
9.2 Middle East and Africa Biologics and Biosimilars Market Status by Manufacturers
9.3 Middle East and Africa Biologics and Biosimilars Market Status by Type (2015-2019)
9.3.1 Middle East and Africa Biologics and Biosimilars Sales by Type (2015-2019)
9.3.2 Middle East and Africa Biologics and Biosimilars Revenue by Type (2015-2019)
9.4 Middle East and Africa Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOLOGICS AND BIOSIMILARS
10.1 Global Economy Situation and Trend Overview
10.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOLOGICS AND BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Biologics and Biosimilars by Major Manufacturers
11.2 Production Value of Biologics and Biosimilars by Major Manufacturers
11.3 Basic Information of Biologics and Biosimilars by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Manufacturer
11.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOLOGICS AND BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Roche
12.1.1 Company profile
12.1.2 Representative Biologics and Biosimilars Product
12.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche
12.2 Eli Lilly
12.2.1 Company profile
12.2.2 Representative Biologics and Biosimilars Product
12.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
12.3 Sanofi-Aventis
12.3.1 Company profile
12.3.2 Representative Biologics and Biosimilars Product
12.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
12.4 Amgen
12.4.1 Company profile
12.4.2 Representative Biologics and Biosimilars Product
12.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
12.5 Novo Nordisk
12.5.1 Company profile
12.5.2 Representative Biologics and Biosimilars Product
12.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.6 AbbVie
12.6.1 Company profile
12.6.2 Representative Biologics and Biosimilars Product
12.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
12.7 Merck
12.7.1 Company profile
12.7.2 Representative Biologics and Biosimilars Product
12.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck
12.8 Pfizer
12.8.1 Company profile
12.8.2 Representative Biologics and Biosimilars Product
12.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
12.9 Johnson & Johnson
12.9.1 Company profile
12.9.2 Representative Biologics and Biosimilars Product
12.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.10 Novartis
12.10.1 Company profile
12.10.2 Representative Biologics and Biosimilars Product
12.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
12.11 Gelgen
12.11.1 Company profile
12.11.2 Representative Biologics and Biosimilars Product
12.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
12.12 Ganlee
12.12.1 Company profile
12.12.2 Representative Biologics and Biosimilars Product
12.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Ganlee
12.13 3sbio
12.13.1 Company profile
12.13.2 Representative Biologics and Biosimilars Product
12.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
12.14 Innovent
12.14.1 Company profile
12.14.2 Representative Biologics and Biosimilars Product
12.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Innovent
12.15 Biotech
12.15.1 Company profile
12.15.2 Representative Biologics and Biosimilars Product
12.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
12.16 Changchun High Tech
12.17 Dong Bao
12.18 CP Guojian
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOLOGICS AND BIOSIMILARS
13.1 Industry Chain of Biologics and Biosimilars
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOLOGICS AND BIOSIMILARS
14.1 Cost Structure Analysis of Biologics and Biosimilars
14.2 Raw Materials Cost Analysis of Biologics and Biosimilars
14.3 Labor Cost Analysis of Biologics and Biosimilars
14.4 Manufacturing Expenses Analysis of Biologics and Biosimilars
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Biologics and Biosimilars in This Report
1.2 Commercial Types of Biologics and Biosimilars
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Erythropoietin
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Downstream Application of Biologics and Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Others
1.4 Development History of Biologics and Biosimilars
1.5 Market Status and Trend of Biologics and Biosimilars 2015-2026
1.5.1 Global Biologics and Biosimilars Market Status and Trend 2015-2026
1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2015-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Biologics and Biosimilars 2015-2019
2.2 Sales Market of Biologics and Biosimilars by Regions
2.2.1 Sales Volume of Biologics and Biosimilars by Regions
2.2.2 Sales Value of Biologics and Biosimilars by Regions
2.3 Production Market of Biologics and Biosimilars by Regions
2.4 Global Market Forecast of Biologics and Biosimilars 2020-2026
2.4.1 Global Market Forecast of Biologics and Biosimilars 2020-2026
2.4.2 Market Forecast of Biologics and Biosimilars by Regions 2020-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Biologics and Biosimilars by Types
3.2 Sales Value of Biologics and Biosimilars by Types
3.3 Market Forecast of Biologics and Biosimilars by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Biologics and Biosimilars by Downstream Industry
4.2 Global Market Forecast of Biologics and Biosimilars by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Biologics and Biosimilars Market Status by Countries
5.1.1 North America Biologics and Biosimilars Sales by Countries (2015-2019)
5.1.2 North America Biologics and Biosimilars Revenue by Countries (2015-2019)
5.1.3 United States Biologics and Biosimilars Market Status (2015-2019)
5.1.4 Canada Biologics and Biosimilars Market Status (2015-2019)
5.1.5 Mexico Biologics and Biosimilars Market Status (2015-2019)
5.2 North America Biologics and Biosimilars Market Status by Manufacturers
5.3 North America Biologics and Biosimilars Market Status by Type (2015-2019)
5.3.1 North America Biologics and Biosimilars Sales by Type (2015-2019)
5.3.2 North America Biologics and Biosimilars Revenue by Type (2015-2019)
5.4 North America Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Biologics and Biosimilars Market Status by Countries
6.1.1 Europe Biologics and Biosimilars Sales by Countries (2015-2019)
6.1.2 Europe Biologics and Biosimilars Revenue by Countries (2015-2019)
6.1.3 Germany Biologics and Biosimilars Market Status (2015-2019)
6.1.4 UK Biologics and Biosimilars Market Status (2015-2019)
6.1.5 France Biologics and Biosimilars Market Status (2015-2019)
6.1.6 Italy Biologics and Biosimilars Market Status (2015-2019)
6.1.7 Russia Biologics and Biosimilars Market Status (2015-2019)
6.1.8 Spain Biologics and Biosimilars Market Status (2015-2019)
6.1.9 Benelux Biologics and Biosimilars Market Status (2015-2019)
6.2 Europe Biologics and Biosimilars Market Status by Manufacturers
6.3 Europe Biologics and Biosimilars Market Status by Type (2015-2019)
6.3.1 Europe Biologics and Biosimilars Sales by Type (2015-2019)
6.3.2 Europe Biologics and Biosimilars Revenue by Type (2015-2019)
6.4 Europe Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Biologics and Biosimilars Market Status by Countries
7.1.1 Asia Pacific Biologics and Biosimilars Sales by Countries (2015-2019)
7.1.2 Asia Pacific Biologics and Biosimilars Revenue by Countries (2015-2019)
7.1.3 China Biologics and Biosimilars Market Status (2015-2019)
7.1.4 Japan Biologics and Biosimilars Market Status (2015-2019)
7.1.5 India Biologics and Biosimilars Market Status (2015-2019)
7.1.6 Southeast Asia Biologics and Biosimilars Market Status (2015-2019)
7.1.7 Australia Biologics and Biosimilars Market Status (2015-2019)
7.2 Asia Pacific Biologics and Biosimilars Market Status by Manufacturers
7.3 Asia Pacific Biologics and Biosimilars Market Status by Type (2015-2019)
7.3.1 Asia Pacific Biologics and Biosimilars Sales by Type (2015-2019)
7.3.2 Asia Pacific Biologics and Biosimilars Revenue by Type (2015-2019)
7.4 Asia Pacific Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Biologics and Biosimilars Market Status by Countries
8.1.1 Latin America Biologics and Biosimilars Sales by Countries (2015-2019)
8.1.2 Latin America Biologics and Biosimilars Revenue by Countries (2015-2019)
8.1.3 Brazil Biologics and Biosimilars Market Status (2015-2019)
8.1.4 Argentina Biologics and Biosimilars Market Status (2015-2019)
8.1.5 Colombia Biologics and Biosimilars Market Status (2015-2019)
8.2 Latin America Biologics and Biosimilars Market Status by Manufacturers
8.3 Latin America Biologics and Biosimilars Market Status by Type (2015-2019)
8.3.1 Latin America Biologics and Biosimilars Sales by Type (2015-2019)
8.3.2 Latin America Biologics and Biosimilars Revenue by Type (2015-2019)
8.4 Latin America Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Biologics and Biosimilars Market Status by Countries
9.1.1 Middle East and Africa Biologics and Biosimilars Sales by Countries (2015-2019)
9.1.2 Middle East and Africa Biologics and Biosimilars Revenue by Countries (2015-2019)
9.1.3 Middle East Biologics and Biosimilars Market Status (2015-2019)
9.1.4 Africa Biologics and Biosimilars Market Status (2015-2019)
9.2 Middle East and Africa Biologics and Biosimilars Market Status by Manufacturers
9.3 Middle East and Africa Biologics and Biosimilars Market Status by Type (2015-2019)
9.3.1 Middle East and Africa Biologics and Biosimilars Sales by Type (2015-2019)
9.3.2 Middle East and Africa Biologics and Biosimilars Revenue by Type (2015-2019)
9.4 Middle East and Africa Biologics and Biosimilars Market Status by Downstream Industry (2015-2019)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOLOGICS AND BIOSIMILARS
10.1 Global Economy Situation and Trend Overview
10.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOLOGICS AND BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Biologics and Biosimilars by Major Manufacturers
11.2 Production Value of Biologics and Biosimilars by Major Manufacturers
11.3 Basic Information of Biologics and Biosimilars by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Manufacturer
11.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOLOGICS AND BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Roche
12.1.1 Company profile
12.1.2 Representative Biologics and Biosimilars Product
12.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche
12.2 Eli Lilly
12.2.1 Company profile
12.2.2 Representative Biologics and Biosimilars Product
12.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
12.3 Sanofi-Aventis
12.3.1 Company profile
12.3.2 Representative Biologics and Biosimilars Product
12.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
12.4 Amgen
12.4.1 Company profile
12.4.2 Representative Biologics and Biosimilars Product
12.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
12.5 Novo Nordisk
12.5.1 Company profile
12.5.2 Representative Biologics and Biosimilars Product
12.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.6 AbbVie
12.6.1 Company profile
12.6.2 Representative Biologics and Biosimilars Product
12.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
12.7 Merck
12.7.1 Company profile
12.7.2 Representative Biologics and Biosimilars Product
12.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck
12.8 Pfizer
12.8.1 Company profile
12.8.2 Representative Biologics and Biosimilars Product
12.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
12.9 Johnson & Johnson
12.9.1 Company profile
12.9.2 Representative Biologics and Biosimilars Product
12.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.10 Novartis
12.10.1 Company profile
12.10.2 Representative Biologics and Biosimilars Product
12.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
12.11 Gelgen
12.11.1 Company profile
12.11.2 Representative Biologics and Biosimilars Product
12.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
12.12 Ganlee
12.12.1 Company profile
12.12.2 Representative Biologics and Biosimilars Product
12.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Ganlee
12.13 3sbio
12.13.1 Company profile
12.13.2 Representative Biologics and Biosimilars Product
12.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
12.14 Innovent
12.14.1 Company profile
12.14.2 Representative Biologics and Biosimilars Product
12.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Innovent
12.15 Biotech
12.15.1 Company profile
12.15.2 Representative Biologics and Biosimilars Product
12.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
12.16 Changchun High Tech
12.17 Dong Bao
12.18 CP Guojian
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOLOGICS AND BIOSIMILARS
13.1 Industry Chain of Biologics and Biosimilars
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOLOGICS AND BIOSIMILARS
14.1 Cost Structure Analysis of Biologics and Biosimilars
14.2 Raw Materials Cost Analysis of Biologics and Biosimilars
14.3 Labor Cost Analysis of Biologics and Biosimilars
14.4 Manufacturing Expenses Analysis of Biologics and Biosimilars
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
